Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

证券代码：002365 证券简称：永安药业 公告编号：2025-43 潜江永安药业股份有限公司 关于年产 4 万吨牛磺酸食品添加剂项目 潜江永安药业股份有限公司（以下简称"公司"）于 2021 年 12 月 2 日召 开第六届董事会第四次会议，审议通过了《关于扩建年产 4 万吨牛磺酸食品添加 剂项目的议案》，同意公司使用自有资金 2.5 亿元人民币扩建年产 4 万吨牛磺酸 食品添加剂项目（以下简称"该项目"），具体内容见公司在中国证监会指定信 息披露媒体巨潮资讯网（http://www.cninfo.com.cn）披露的《关于扩建年产 4 万吨牛磺酸食品添加剂项目的公告》（公告编号：2021-62）。2023 年 2 月 2 日， 公司披露了《关于取得年产 4 万吨牛磺酸食品添加剂扩建项目安评环评批复的公 告》（公告编号：2023-07），该项目已取得安评环评批复。 公司建设该项目旨在通过提升产能的同时，解决原生产线的瓶颈问题，并进 行技术升级，从而达到节能降耗、降低成本、提高质量、增强竞争力的目的。但 鉴于近年来牛磺酸价格持续下滑，公司根据该项目实际建设情况以及当前经营环 境，经审慎研究，决定将原整体扩建项 ...

Core Insights - The A-share market showed a steady performance in the first half of 2025, with notable gains from two Hubei-listed companies, Jiuling Technology and Yong'an Pharmaceutical, achieving increases of 306.72% and 234.79% respectively [1][4]. Jiuling Technology - Jiuling Technology, a high-tech enterprise focused on magnetic materials and precision components, saw its stock price rise by 306.72% in the first half of 2025, ranking fourth in terms of stock performance [2]. - The company's Q1 2025 financial report indicated a revenue of 36.31 million yuan, a year-on-year increase of 4.4%, and a net profit of 6.27 million yuan, up 19.6% year-on-year [2]. - Jiuling Technology has established stable partnerships with major automotive manufacturers, supplying core components to brands like FAW-Volkswagen and Great Wall Motors, benefiting from the booming demand in the new energy vehicle sector [3]. Yong'an Pharmaceutical - Yong'an Pharmaceutical's stock price surged by 234.79% in the first half of 2025, with a dramatic increase from 9 yuan to 28 yuan within two and a half months [4]. - The company specializes in active pharmaceutical ingredients and intermediates, with a significant market share in taurine production, which has seen increased demand due to regulatory changes in the U.S. [4]. - Yong'an Pharmaceutical's production capacity for taurine is 58,000 tons per year, accounting for approximately 50% of the market share, with 60.23% of its revenue coming from overseas sales [4]. Overall Performance of Hubei-listed Companies - Other Hubei-listed companies also performed well, with Yizhi Moyou achieving an increase of 188.42% [5]. - The strong performance of Hubei-listed companies is attributed to local policy support, industrial upgrades, and technological innovation, with the province promoting sectors like biomedicine and high-end equipment manufacturing [5].

Group 1 - The A-share market showed steady progress in the first half of 2025, with major indices such as the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index all experiencing increases, leading to an overall rise in market capitalization and a steady growth in the number of listed companies [2][3] - Approximately 3,800 companies saw their stock prices increase, with over 1,700 companies achieving a rise of more than 20%, and 136 companies doubling their stock prices [3] - The top-performing stock was United Chemical, which experienced a remarkable increase of 437.83%, followed by Shuyou Shen with a 403.10% rise, and *ST Yushun with a 355.06% increase [3][4] Group 2 - The non-ferrous metals sector led the market with an impressive cumulative increase of 18.12%, driven by rising metal prices and strong performance in gold, which peaked at $3,500 per ounce in April [6] - Other sectors such as banking, national defense, and media also performed well, with respective increases of 13.10%, 12.99%, and 12.77%, and several banking stocks seeing gains of over 20% [7] - Notably, eight companies in the national defense sector saw their stock prices double, while three companies in the media sector also achieved similar results [7] Group 3 - Analysts predict that the capital market will continue to present opportunities in the second half of the year, with expectations for a more active market and potential for further index growth beyond 3,400 points [8][9] - The focus is expected to shift towards core assets, including traditional consumer stocks and leading technology companies, as the market transitions towards a trend-driven environment [8][9] - Institutions are optimistic about the market outlook, anticipating a bull market in both Hong Kong and A-share markets starting in the fourth quarter of 2025, with a shift from small-cap stocks to core assets [9]

Core Points - The company plans to distribute cash dividends to shareholders at a rate of 1.00 yuan (including tax) for every 10 shares held, totaling 28,914,515.00 yuan (including tax) [1][2][3] - The total share capital for the dividend distribution is based on 289,145,150 shares after excluding 5,537,350 shares held in the repurchase account [1][2] - The cash dividend per share after the distribution will be calculated as 0.0981209 yuan per share, reflecting a decrease in the dividend per share due to the exclusion of repurchased shares [2][6] Dividend Distribution Plan - The dividend distribution plan was approved at the 2024 annual shareholders' meeting, with no stock bonuses or capital increases planned [2][3] - The record date for the dividend distribution is set for July 8, 2025, and the ex-dividend date is July 9, 2025 [3][4] - The distribution will be directly credited to shareholders' accounts through their custodial securities companies [4] Taxation and Adjustments - The company will not withhold individual income tax on dividends for certain investors, with tax obligations calculated based on holding periods upon stock transfer [3][6] - If there are changes in total share capital due to stock options, convertible bonds, or share repurchases before the dividend distribution, the total dividend amount will be adjusted accordingly [2][3]

证券代码：002365 证券简称：永安药业 公告编号：2025-42 潜江永安药业股份有限公司 税），其余可分配利润转入下一年度，不送股不转增。本次利润分配预案披露后 至权益分派实施前，如因股权激励行权、可转债转股、股份回购等导致公司股 本总额发生变动的，按照分配比例不变的原则对分配总额进行调整，实际分红 总额按照后续权益分派实施为准。 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 根据《公司法》和《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》等规定，回购专用证券账户中的股份不享有参与利润分配等权利。潜江永 安药业股份有限公司（以下简称 "公司"）本次权益分派按照固定比例方式分 配的原则，以公司现有总股本 294,682,500 股剔除回购专用证券账户上已回购 股份 5,537,350 股后的 289,145,150 股为基数，向全体股东按每 10 股派发现金 股利 1.00 元（含税），不送红股，不以公积金转增股本，本次实际派发现金总 额 28,914,515.00 元（含税）。 因公司回购专用 ...

Group 1 - The legal opinion letter is issued by Shanghai Jintiancheng (Wuhan) Law Firm regarding the 2024 annual general meeting of shareholders of Qianjiang Yong'an Pharmaceutical Co., Ltd. [1][2] - The law firm confirms that it has fulfilled its legal responsibilities and conducted necessary verifications for the meeting, ensuring the accuracy and legality of the conclusions presented in the legal opinion [2][12] - The meeting was convened by the company's board of directors, with the decision made during the sixth meeting of the seventh board on April 28, 2025 [2][5] Group 2 - The notice for the annual general meeting was published on April 29, 2025, detailing the meeting's convenor, date, time, and other relevant information, with more than 20 days' notice given [3][5] - The meeting took place on June 24, 2025, at the company's conference room, presided over by the acting chairman [3][4] - The meeting utilized a combination of on-site and online voting methods, with specific time slots allocated for each [4][6] Group 3 - A total of 561 shareholders and their proxies attended the meeting, representing 76,031,566 shares, which is 26.2953% of the total voting shares [5][6] - The online voting system recorded 548 participants, representing 2,205,550 shares, or 0.7628% of the total voting shares [6][7] - The meeting's agenda included proposals that were within the authority of the shareholders' meeting and consistent with the published notice [7][12] Group 4 - The voting results showed that 78,104,116 shares were in favor of the proposals, accounting for the majority of the valid voting shares [8][12] - Among the minority investors, 12,607,582 shares voted in favor, representing 98.9561% of the valid votes from small shareholders [8][10] - The legal opinion concludes that the meeting's procedures, qualifications of the convenor, attendees, and voting processes comply with relevant laws and regulations, confirming the validity of the voting results [12]

Meeting Overview - The shareholder meeting of Yong'an Pharmaceutical Co., Ltd. was held on June 24, 2025, with both on-site and online voting options available [1] - A total of 561 shareholders participated, representing 78,237,116 shares, which is 27.0581% of the total voting shares [1] Proposal Review and Voting Results - The following proposals were reviewed and approved during the meeting: - The 2024 Board of Directors Work Report was approved with 99.8300% in favor [2] - The 2024 Supervisory Board Work Report was approved with 99.8328% in favor [2] - The 2024 Annual Report and its summary were approved with 99.8855% in favor [3] - The 2024 Financial Settlement Report was approved with 99.8828% in favor [4] - The 2024 Profit Distribution Plan was approved with 99.8212% in favor [5] - The reappointment of the accounting firm was approved with 99.8598% in favor [6] - The proposal for using self-owned funds for entrusted financial management was approved with 99.8250% in favor [6] Small Shareholder Voting - Small shareholders also participated in the voting, with the following results: - For the 2024 Board of Directors Work Report, 12,607,582 shares were in favor, representing 0.5949% of the small shareholders' voting rights [2] - For the 2024 Supervisory Board Work Report, 12,609,782 shares were in favor, representing 0.5753% of the small shareholders' voting rights [3] - For the 2024 Annual Report, 12,650,982 shares were in favor, representing 0.2527% of the small shareholders' voting rights [4] - For the 2024 Financial Settlement Report, 12,648,882 shares were in favor, representing 0.2363% of the small shareholders' voting rights [5] - For the 2024 Profit Distribution Plan, 12,600,682 shares were in favor, representing 0.2865% of the small shareholders' voting rights [6] - For the reappointment of the accounting firm, 12,630,882 shares were in favor, representing 0.3799% of the small shareholders' voting rights [6] - For the entrusted financial management proposal, 12,603,682 shares were in favor, representing 0.4961% of the small shareholders' voting rights [6] Legal Verification - The meeting was witnessed by lawyers from Shanghai Jintiancheng (Wuhan) Law Firm, confirming that the meeting's procedures and voting results were in compliance with relevant laws and regulations [6]

地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二四年年度股东会的 法律意见书 本所同意将本法律意见书与本次股东会的决议一并进行公告，并依法对发表 的法律意见承担相应法律责任。 鉴此，本所律师根据上述法律、法规、规章及规范性文件的要求，按照律师 行业公认的业务标准、道德规范和勤勉尽责精神，现出具法律意见如下： 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二四年年度股东会的 法律意见书 致：潜江永安药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受潜江永安药业 股份有限公司（以下简称"公司"）的委托，委派本律师出席公司二○二四年年 度股东会（下简称"本次股东会"），就公司召开本次股东会的有关事宜，根据 《中华人民共和国公司法》（以下简称《公司法》）《上市公司股东会规则》（以 下简称《股东会规则》）等法律、法规、规章和其他规范性文件以及《潜江永安 药业股份有限公司章程》（以下简称《公司章程 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-41 潜江永安药业股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2025年6月24日（星期二）14:00 网络投票时间：2025年6月24日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6 月24日上午9:15—9:25,9:30-11:30 和下午13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年6月24日 9:15—15:00期间的任意时间。 2、现场会议召开地点：湖北省潜江经济开发区广泽大道2号潜江永安药业股 份有限公司（以下简称"公司"）二楼会议室 2、中小股东（指除公司董事、监事、高级管理人员以及单独或者合计持有 公司 5%以上股份的股东以外的其他股东）出席会议情况 通过现场和网络投票的股东561人，代表 ...